Loading...
•
Dec 31, 2024
Journey Medical Q4 2024 Earnings Report
Journey Medical returned to profitability in Q4 2024 with a strong quarter driven by cost control and pre-launch activities for Emrosi.
Key Takeaways
Journey Medical posted a surprise profit in Q4 2024, reversing previous losses. Revenue came in at $13.6M and the company reported net income of $1.5M, helped by lower R&D spend and tight SG&A management. The Emrosi launch remains a key catalyst for 2025.
Journey posted net income of $1.5M in Q4 2024, reversing prior losses.
Revenue for Q4 was $13.6M, bringing full-year revenue to $56.1M.
Emrosi received FDA approval and began initial distribution in Q4.
Cost management and lower R&D spend contributed to positive EPS.
Forward Guidance
Journey expects to accelerate revenue growth in 2025 following the commercial launch of Emrosi, targeting sustainable profitability.
Positive Outlook
- FDA approval of Emrosi expected to drive revenue in 2025
- Initial Emrosi prescriptions already filled in Q4
- Q4 marked a return to net profitability
- Full promotional push for Emrosi planned in April 2025
- Cost structure optimized for launch readiness
Challenges Ahead
- FY revenue declined 29% YoY due to lower royalties and legacy product erosion
- Higher rebate costs continue to impact product revenue margins
- Cash position decreased $7.1M YoY
- Dependence on successful Emrosi launch to sustain momentum
- Some legacy dermatology products face ongoing volume pressure
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...